

FINAL NOVEMBER 2020 THERAPEUTIC DRUG CLASSES

ALZHEIMER'S AGENTS
ANTICONSULSANTS
ANTIDEPRESSANTS, OTHER
ANTIDEPRESSANTS, SSRIs
ANTIHISTAMINES, MINIMALLY SEDATING
ANTIHYPERTENSIVES, SYMPATHOLYTIC
ANTIHYPERTENSIVES, ORAL
ANTIPARKINSON'S AGENTS
ANTIPSORIATICS, ORAL
ANTIPSORIATICS, TOPICAL
ANTIPSYCHOTICS
ANXIOLYTICS
BILE SALTS
BRONCHODILATORS, BETA AGONIST
COPD AGENTS
COUGH AND COLD/NARCOTICS
CYTOKINE AND CAM ANTAGONISTS
EPINEPHRINE, SELF-INJECTED
ERYTHROPOIESIS STIMULATING PROTEINS
GLUCOCORTICOIDS, INHALED
GLUCOCORTICOIDS, ORAL
HISTAMINE II RECEPTOR BLOCKERS
IMMUNOMODULATORS FOR ATOPIC DERMATITIS
IMMUNOMODULATORS, TOPICAL
INTRANASAL RHINITIS AGENTS
LEUKOTRIENE MODIFIERS
METHOTREXATE
NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)
NSAIDS
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
OPHTHALMIC ANTIBIOTICS
OPHTHALMIC ANTIINFLAMMATORIES
OPHTHALMIC ANTIINFLAMMATORIES/IMMUNOMODULATORS
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
OPHTHALMICS, GLAUCOMA AGENTS
OTIC ANTIBIOTICS
OTIC ANTI-INFECTIVES
SEDATIVE HYPNOTICS
STERIODS, TOPICAL-HIGH POTENCY
STERIODS, TOPICAL-LOW POTENCY
STERIODS, TOPICAL-MEDIUM POTENCY
STERIODS, TOPICAL-VERY HIGH POTENCY
STIMULANTS AND RELATED AGENTS

POTENTIAL NEW CLASS

MOVEMENT DISORDERS